|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Eli Lilly and Company |
|---|---|
| Information provided by: | Eli Lilly and Company |
| ClinicalTrials.gov Identifier: | NCT00065312 |
Purpose
The purpose of this study is to determine if an investigational drug is safe and efficacious for poorly controlled type 2 diabetes mellitus.
| Condition | Intervention | Phase |
|---|---|---|
|
Diabetes Mellitus, Non-Insulin-Dependent |
Drug: naveglitazar |
Phase II |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Treatment |
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
Show 42 Study Locations
More Information
| ClinicalTrials.gov Identifier: | NCT00065312 History of Changes |
| Other Study ID Numbers: | 5837, H7R-MC-GCBD |
| Study First Received: | July 21, 2003 |
| Last Updated: | July 18, 2006 |
| Health Authority: | United States: Food and Drug Administration |
|
Type 2 diabetes |
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases |
Endocrine System Diseases Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |